Evidence map›Paper›PMID 25912539›Full record

ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2015

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.

Akihiro Shiina, Nobuhisa Kanahara, Tsuyoshi Sasaki, Yasunori Oda, Tasuku Hashimoto, Tadashi Hasegawa, Taisuke Yoshida, Masaomi Iyo, Kenji Hashimoto

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01716858 (Sulforaphane-rich Broccoli Sprout Extract for Schizophrenia), which is not on this map. Cited by 66 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01716858 phase2completednot on this map

Sulforaphane-rich Broccoli Sprout Extract for Schizophrenia

TypeinterventionalSponsorChiba UniversityRan2012 to 2014Enrolled10ConditionsSchizophreniaArmsSulforaphane-rich Broccoli Sprout Extract
3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. The Anti-AGEing and RAGEing Potential of Isothiocyanates.Molecules (Basel, Switzerland) · 2024
    Review
  18. Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Akihiro ShiinaDepartment of Child Psychiatry, Chiba University Hospital, Chiba, Japan.
Nobuhisa KanaharaDivision of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Chiba, Japan.
Tsuyoshi SasakiDepartment of Child Psychiatry, Chiba University Hospital, Chiba, Japan.
Yasunori OdaDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tasuku HashimotoDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tadashi HasegawaDepartment of Psychiatry, Chiba University Hospital, Chiba, Japan.
Taisuke YoshidaKisarazu Hospital, Japan.
Masaomi IyoDepartment of Child Psychiatry, Chiba University Hospital, Chiba, Japan.
Kenji Hashimoto
Center for Forensic Mental Health, Chiba University · JPChiba University Hospital · JPChiba University · JPKisarazu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSchizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia.

methodsWe recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8.

resultsA total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants.

conclusionsThis result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia.

Indexed as

Clinical trialCogStateExecutive functionSchizophreniaSulforafan

Identifiers

PMID25912539
PMCPMC4423155
OpenAlexW2334107882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.